• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, November 17, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

A new approach to targeting cancer cells

Bioengineer by Bioengineer
May 19, 2019
in Cancer
Reading Time: 3 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

UC Riverside researchers develop new drugs that target therapeutically relevant protein surfaces

IMAGE

Credit: Pellecchia lab, UC Riverside.

RIVERSIDE, Calif. — A University of California, Riverside, research team has come up with a new approach to targeting cancer cells that circumvents a challenge faced by currently available cancer drugs.

A cancer target is often a rogue protein that signals cancer cells to proliferate uncontrollably and invade organs. Modern cancer drugs have emerged that work by striking a tight bond between the drug and a particular amino acid called cysteine, one of the 20 natural amino acids that constitute our proteins. Cysteine is unique in that it can react with specific organic functional groups to form a strong molecular bond.

Only a few new cancer drugs that target cysteine have been recently approved by the Food and Drug Administration, or FDA.  A challenge cancer researchers face is that cysteine is rarely found within binding sites of cancer targets, limiting the application of this approach to only a few drug targets.

The UC Riverside research team has now met this challenge by exploring the development of drugs that target other potentially reactive amino acids, such as lysine, tyrosine, or histidine, which occur more often within the binding site of the target.

The researchers also addressed another challenge: The target they used for proof of concept was a protein-protein interaction, or PPI, target. PPIs represent a large class of possible therapeutic targets for which designing effective drugs is particularly difficult. This is because PPIs lack a well-defined and deep-binding pocket onto which drugs can de designed to bind tightly.

“To date, there is only one drug approved by the FDA that was designed to antagonize — or block — a PPI target,” said Maurizio Pellecchia, a professor of biomedical sciences in the School of Medicine, who led the research. “Only a few others have entered clinical trials. Our approach provides novel and effective avenues to derive potent and selective PPI antagonists by designing drugs that can react with lysine, tyrosine, or histidine residues that are ubiquitously present at binding interfaces of PPIs.”

Study results appear in the Journal of Medicinal Chemistry.

Pellecchia, who holds the Daniel Hays Chair in Cancer Research at UCR, explained that academic researchers, the biotechnology industry, and pharmaceutical companies are heavily pursuing the design of “covalent drugs” that bind irreversibly with their targets. Those that target cancer cells most often target cysteine because it is more reactive than all other amino acids in a protein target. Oncology drugs such as Osimertinib, Ibrutinib, Neratinib, and Afatinib have all been approved in very recent years by the FDA, he said, and all target a cysteine that is present on the binding site of their respective targets.

“Our work widens the available target space beyond cysteine,” he added. “Such covalent agents could represent significant stepping stones in the development of novel drug candidates against PPIs, which represent an untapped large class of therapeutic targets not only in oncology, but also in other conditions including neurodegenerative and inflammatory diseases.”

###

Pellecchia was joined in the research by UCR School of Medicine scientists Luca Gambini, Carlo Baggio, and Ahmed F. Salem; biomedical sciences graduate student Parima Udompholkul; and Jefferson P. Perry, an assistant professor of biochemistry, and biochemistry graduate student Jennifer Jossart.

The study was supported by grants to Pellecchia from the National Institutes of Health and the City of Hope — UC Riverside Biomedical Research Initiative.

The University of California, Riverside (http://www.ucr.edu) is a doctoral research university, a living laboratory for groundbreaking exploration of issues critical to Inland Southern California, the state and communities around the world. Reflecting California’s diverse culture, UCR’s enrollment is more than 24,000 students. The campus opened a medical school in 2013 and has reached the heart of the Coachella Valley by way of the UCR Palm Desert Center. The campus has an annual statewide economic impact of almost $2 billion. To learn more, email news@ucr.edu.

Media Contact
Iqbal Pittalwala
iqbal@ucr.edu

Tags: BiochemistryBiotechnologyBreast CancercancerCarcinogensMedicine/HealthPharmaceutical SciencesPharmaceutical/Combinatorial ChemistryProstate Cancer
Share12Tweet8Share2ShareShareShare2

Related Posts

Three-Gene Mitochondrial RNA Modification Signature Predicts Hepatocellular Carcinoma Prognosis

Three-Gene Mitochondrial RNA Modification Signature Predicts Hepatocellular Carcinoma Prognosis

November 17, 2026
High-Grade Meningiomas With NF2 Alterations Frequently Progress After Stereotactic Radiosurgery

High-Grade Meningiomas With NF2 Alterations Frequently Progress After Stereotactic Radiosurgery

November 17, 2026

Mesenchymal Programs Correlate With High Metabolic Tumor Volume in Pancreatic Cancer

November 17, 2026

Comprehensive Genomic Profiling Reveals Lower Mutation Burden in Early-Onset Colorectal Cancer

November 17, 2026
Please login to join discussion

POPULAR NEWS

  • Brain Hemorrhage Location Dictates Distinct Vascular Causes Outcomes and Treatment Responses

    Brain Hemorrhage Location Dictates Distinct Vascular Causes Outcomes and Treatment Responses

    29 shares
    Share 12 Tweet 7
  • Most Cost Savings in Medical Feature Selection Stem From Dataset Artifacts

    29 shares
    Share 12 Tweet 7
  • Financial Technology Adoption Expands Universal Health Coverage Across WAEMU Countries

    29 shares
    Share 12 Tweet 7
  • Three-Gene Mitochondrial RNA Modification Signature Predicts Hepatocellular Carcinoma Prognosis

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Microglia Study Identifies FKBP5 as a Regulator of Alzheimer’s Inflammation

Holmium Substitution Improves SmFeO3 Supercapacitor Electrochemical Performance in KI/KOH Electrolyte

Comorbidities Associated With Lower RSV Humoral and Cellular Immunity in Older Adults

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.